erythropoietin stimulating agents Market Size, Trends [2030]

Segments - Erythropoietin Stimulating Agents Market by Types (Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, and Others), Applications (Cancer, Renal Disorders, Anti-retroviral Treatment, Neural Diseases, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) – Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021-2028

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

The global erythropoietin stimulating agents market size is anticipated to expand at a significant CAGR during the forecast period, 2021-2028. The growth of the market is attributed to increasing incidence of kidney diseases, chemotherapy, and major surgeries.

Erythropoietin Stimulating Agents summary

Erythropoietin (EPO) is a hormone that is produced mainly in kidneys which stimulates production and maintenance of red blood cells. It is a protein coding gene. EPO stimulating agents (ESAs) are mainly used often for people with long term kidney disease and anemia. Normal range of EPO is between 2.6 and 18.5 milliunits per milliliter (mU/mL).

The acute kidney injury (AKI) and anemia patients avoid EPO stimulating agents (ESAs, as these patients are unsuitable to effective response to ESAs due to the inflammation. Thus, the risks associated with ESA treatments are expected to outweigh the potential benefits.

Market Trends, Drivers, Restraints and Opportunities

Increasing number of patients suffering from anemia and increasing application in HIV infections are expected to drive the market growth in the coming years.
Rising prevalence of heart diseases and high blood pressure are estimated to spur the market growth in the coming years.
High price of treatments such as chemotherapy and kidney surgery, namely nephrectomy, can hinder the market growth.
Increasing side effects of ESAs is estimated to restrain the market growth.
Growing focus on value-based medicine is anticipated to create significant opportunities for the market players.

Scope of the Report

The report on the global erythropoietin stimulating agents market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Erythropoietin Stimulating Agents Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2020
Historic Data	2018–2019
Forecast Period	2021–2028
Segmentation	Types (Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, and Others) and Applications (Cancer, Renal Disorders, Anti-retroviral Treatment, Neural Diseases, and Others)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	Johnson and Johnson; Pfizer Inc.; Amgen Inc.; Thermo Fisher Scientific; F. Hoffmann La Roche Ltd.

Erythropoietin Stimulating Agents Market Segment Insights

Darbepoetin alfa segment to hold a significant market share

On the basis of types, the market is divided into epoetin alfa, epoetin beta, darbepoetin alfa, and others. The epoetin alfa segment is anticipated to hold a key share of the market in the coming years due to increasing utilization for treatment of anemia, which is caused by chemotherapy. However, the darbepoetin alfa segment is anticipated to expand at a rapid pace during the forecast period due to increasing use for the treatment of chronic kidney diseases.

Anti-retroviral treatment segment is expected to grow at a rapid pace

Based on application, the market is divided into cancer, renal disorders, anti-retroviral treatment, neural diseases, and others. The cancer segment is expected to represent a key share of the market in the upcoming years due to reduced pain and other problem caused by tumor and to kill cancer cells that have spread to other parts of the body. On the other hand, the anti-retroviral treatment segment is anticipated to expand at a rapid pace during the forecast period to prevent HIV virus from multiplying and destroying infection fighting cells.

North America is estimated to account a major market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to constitute a key share of the market in the upcoming years due to increasing number of uncontrolled high blood pressure patients in the US. The market in Asia Pacific is expected to grow at a robust rate during the forecast period owing to rapid development in healthcare infrastructure such as India and China.

Erythropoietin Stimulating Agents region

Segments

Segments Covered in the Report

The global erythropoietin stimulating agents market has been segmented on the basis of

Types

Epoetin Alfa
Epoetin Beta
Darbepoetin Alfa
Others

Applications

Cancer
Renal Disorders
Anti-retroviral Treatment
Neural Diseases
Others

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

Johnson and Johnson
Pfizer Inc.
Amgen Inc.
Thermo Fisher Scientific
F. Hoffmann La Roche Ltd.

Competitive Landscape

Key players competing in the erythropoietin stimulating agents market includes Johnson and Johnson; Pfizer Inc.; Amgen Inc.; Thermo Fisher Scientific; F. Hoffmann La Roche Ltd.
Some of these players are engaging in business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market share.
In February 2020, Samsung Medical Center studied on the efficacy of intravenous iron injection, Ferinject, in cancer patients with anemia.

Erythropoietin Stimulating Agents keyplayers

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. erythropoietin stimulating agents Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. erythropoietin stimulating agents Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. erythropoietin stimulating agents Market - Supply Chain
  4.5. Global erythropoietin stimulating agents Market Forecast
     4.5.1. erythropoietin stimulating agents Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. erythropoietin stimulating agents Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. erythropoietin stimulating agents Market Absolute $ Opportunity
5. Global erythropoietin stimulating agents Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. erythropoietin stimulating agents Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global erythropoietin stimulating agents Demand Share Forecast, 2019-2026
6. North America erythropoietin stimulating agents Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America erythropoietin stimulating agents Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America erythropoietin stimulating agents Demand Share Forecast, 2019-2026
7. Latin America erythropoietin stimulating agents Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America erythropoietin stimulating agents Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America erythropoietin stimulating agents Demand Share Forecast, 2019-2026
8. Europe erythropoietin stimulating agents Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe erythropoietin stimulating agents Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe erythropoietin stimulating agents Demand Share Forecast, 2019-2026
9. Asia Pacific erythropoietin stimulating agents Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific erythropoietin stimulating agents Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific erythropoietin stimulating agents Demand Share Forecast, 2019-2026
10. Middle East & Africa erythropoietin stimulating agents Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa erythropoietin stimulating agents Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa erythropoietin stimulating agents Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global erythropoietin stimulating agents Market: Market Share Analysis
  11.2. erythropoietin stimulating agents Distributors and Customers
  11.3. erythropoietin stimulating agents Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Johnson and Johnson
     11.4.2. Pfizer Inc.
     11.4.3. Amgen Inc.
     11.4.4. Thermo Fisher Scientific
     11.4.5. F. Hoffmann La Roche Ltd.